Pharma analytics powering a 360-degree view of your projects, KPIs and strategic goals

10 Essential dashboards for every pharma R&D portfolio management PMO

Well-designed data analytics in project management is no longer a reporting convenience. It is a strategic control tower for project portfolio performance. In complex organizations, where capital allocation, resource constraints, and regulatory pressures intersect, decision velocity depends on real-time visibility. Without a structured PMO project tracking dashboard, portfolio discussions rely on fragmented spreadsheets, static presentations, and subjective updates.For PMO leaders and senior project professionals, the question is not whether to implement a dashboard, but how to design one that scales governance and enables strategic alignment. A mature PMO dashboard connects execution data to business outcomes, making portfolio trade-offs transparent and defensible. It transforms status reporting into performance management.What Is a PMO Dashboard?A PMO dashboard is a structured, visual decision-support layer that consolidates project, financial, risk, and resource data into actionable portfolio insights.In a pharma R&D context, a dashboard must:Integrate clinical, financial, and strategic dataReflect phase-gated development realitiesIncorporate Probability of Technical and Regulatory Success (PTRS)Present risk-adjusted financial metrics (e.g., rNPV)Enable scenario modelingUnlike traditional project dashboards focused on schedule and budget, an R&D PMO dashboard must support questions such as:Where should we allocate the next $100M?Which asset creates concentration risk?What is the impact of accelerating Phase II by 6 months?Are we over-indexed in early-stage assets?Are we realizing the intended benefits?Operational dashboards focus on day-to-day execution. They highlight schedule variance, cost variance, milestone adherence, issue logs, and resource utilization. These views are often used by project managers and program leads to monitor delivery discipline.Executive-level dashboards operate at different altitudes. They aggregate portfolio-level KPIs, investment distribution, strategic alignment scores, benefit realization trends, and risk exposure summaries. Their purpose is not task tracking, but investment governance and performance oversight.A robust PMO dashboard integrates data from Project Portfolio Management (PPM) systems, financial systems, timesheets, and risk registers. The outcome is a single source of truth for portfolio performance, enabling consistent conversations across leadership forums.The 10 Important pharma Dashboards Every PMO n life sciences Should HaveThe following dashboards were selected based on three criteria: executive relevance, R&D specificity, and measurability. Each supports distinct governance decisions and should be integrated into a coherent portfolio reporting framework.Portfolio Investment Allocation DashboardObjective: The Portfolio Investment Allocation Dashboard helps ensure that financial and strategic resources are distributed optimally across a pharma R&D portfolio. It enables the PMO and executives to monitor whether investments align with therapeutic priorities, risk appetite, and long-term pipeline strategy. By visualizing capital allocation across modalities, phases, and internal versus partnered assets, it highlights areas of over- or under-investment. This dashboard also supports scenario-based reallocation decisions to maximize portfolio value while managing concentration risk.Key KPIs to Monitor:Budget vs. Actual Spend by therapeutic area, development phase, and modalityAllocation Across Phases (Discovery → Phase I–III → Regulatory)Internal vs. Partnered Asset Investment RatioRisk-Adjusted Investment Distribution (e.g., rNPV-weighted allocation)Concentration Risk Index (exposure to top 3–5 assets) 2. Clinical Milestone Performance DashboardObjective: The Clinical Milestone Performance Dashboard tracks the operational execution of clinical trials to ensure that studies progress on schedule and within defined parameters. It provides visibility into enrollment, site activation, and critical path timelines, helping PMOs identify delays or bottlenecks early. By monitoring milestone adherence across the portfolio, it allows leaders to assess program predictability and take corrective actions to avoid downstream impacts on time-to-market and overall portfolio value. This dashboard also supports scenario analysis for risk mitigation and resource planning in ongoing trials.Key KPIs to Monitor:Enrollment Velocity vs. Planned Targets (patients recruited per site over time)First Patient In (FPI) / Last Patient Out (LPO) VarianceSite Activation Timelines (planned vs. actual)Critical Path Slippage (deviation from projected milestones)Trial Completion Probability or PTRS-based Milestone Status3. Resource Capacity & Utilization DashboardObjective: The Resource Capacity & Utilization Dashboard helps PMOs ensure that human and operational resources are optimally allocated across the R&D portfolio. It provides visibility into functional workloads, skill availability, and potential bottlenecks, enabling proactive adjustments before delays occur. By monitoring both internal teams and outsourced resources, the dashboard ensures projects are adequately staffed and aligned with strategic priorities. It also supports scenario planning, helping executives assess the impact of shifting resources between high-value or time-sensitive projects.Key KPIs to Monitor:FTE Demand vs. Capacity by function (clinical operations, biostatistics, regulatory, etc.)Resource Utilization Rate (percentage of available hours allocated to active projects)Skill Gap Heatmaps (identifying critical resource shortages)Outsourcing vs. Internal Resource MixOvercommitment Index (projects exceeding available capacity)4. Risk and Issue Management DashboardObjective: The Risk and Issue Management Dashboard provide a centralized view of potential and ongoing risks across the R&D portfolio, helping PMOs proactively identify, assess, and mitigate threats to project timelines, costs, and outcomes. It tracks both the probability and impact of risks, enabling teams to prioritize critical issues and take corrective actions before they affect portfolio performance. By monitoring issues in real time, the dashboard supports transparency, accountability, and strategic decision-making across projects and therapeutic areas. It also helps in evaluating the effectiveness of mitigation plans and risk response strategies.Key KPIs to Monitor:Number of Active Risks and Issues by project, phase, and therapeutic areaRisk Severity and Probability Scores (high, medium, low)Open vs. Closed Issue Count and Resolution TimeMitigation Plan Effectiveness (percentage of risks with approved and executed mitigation strategies)Risk Exposure Trend (portfolio-level view of risk concentration over time)5. Portfolio cost dashboardObjective: The Portfolio Cost Dashboard provides a consolidated view of total R&D spend across the portfolio, enabling PMOs to monitor financial performance at both asset and portfolio levels. It helps ensure that actual spending aligns with approved budgets and long-term financial plans, while highlighting cost overruns or inefficiencies early. By tracking spend across phases, therapeutic areas, and programs, the dashboard supports better financial governance and prioritization decisions. It also enables forward-looking cost forecasting, helping leadership anticipate funding needs and optimize capital allocation.Key KPIs to Monitor:Total Portfolio Spend vs. Approved BudgetCost Variance by asset, phase, and therapeutic areaEstimate at Completion (EAC) vs. Baseline BudgetCost per Phase / Cost per AssetBurn Rate Trends (monthly/quarterly spend velocity)6. Risk-Adjusted Value DashboardObjective: The Risk-Adjusted Value Dashboard enables PMOs and leadership to evaluate the true economic potential of the R&D portfolio by incorporating uncertainty into financial projections. Instead of relying on deterministic forecasts, it applies to probability factors, such as Probability of Technical and Regulatory Success (PTRS) to estimate expected value. This allows decision-makers to compare assets on a like-for-like basis, prioritize high-value programs, and identify concentration risks within the portfolioKey KPIs to Monitor:Risk-Adjusted Net Present Value (rNPV)PTRS (Probability of Technical & Regulatory Success)Expected Commercial Value Value Concentration IndexSensitivity Analysis Outputs7. Scenario Planning & What-If DashboardObjective: The Scenario Planning & What-If Dashboard enables PMOs and executives to evaluate the impact of strategic decisions before committing resources. It allows users to simulate changes, such as accelerating or delaying assets, reallocating budgets, or adjusting resource capacity, and understand how these shifts affect portfolio value, timelines, and risk exposure. By integrating financial, clinical, and resource variables, the dashboard supports data-driven trade-off discussions during governance reviews. It also helps organizations prepare for uncertainty by comparing multiple future scenarios and identifying the most resilient portfolio strategy.Key KPIs to Monitor:Portfolio Value by Scenario Impact of Acceleration/Delay on Time-to-MarketBudget Reallocation EffectsResource Rebalancing OutcomesSensitivity Analysis Results8. Regulatory Dossier Readiness DashboardObjective: The Regulatory Dossier Readiness Dashboard provides a comprehensive view of how prepared an asset is for regulatory submission. It helps PMOs and regulatory teams track the completeness, quality, and timeliness of all required modules and supporting documentation. By highlighting gaps, dependencies, and risks in submission readiness, the dashboard enables proactive issue resolution and ensures alignment with planned submission timelines. It also supports cross-functional coordination across clinical, CMC, and regulatory teams to avoid last-minute delays.Key KPIs to Monitor:Dossier Completeness Submission Readiness Status (on-track, at-risk, delayed)Document Approval Cycle TimeNumber of Open Gaps/Deficiencies prior to submissionRegulatory Milestone Adherence (planned vs. actual submission timelines)9. External Innovation & Alliance DashboardObjective: The External Innovation & Alliance Dashboard provides visibility into the performance and contribution of partnered or in-licensed assets within the R&D portfolio. It helps PMOs and leadership monitor how collaborations, licensing deals, and strategic partnerships are delivering value against expectations. By tracking milestone achievements, financial commitments, and asset progression, the dashboard ensures that external innovation aligns with portfolio priorities. It also supports risk management by identifying underperforming partnerships or potential delays in externally sourced assets.Key KPIs to Monitor:In-Licensed vs. Internal Asset Performance (progression through phases, clinical success)Deal Milestone Payments vs. ForecastPartnership Milestone Adherence (timelines for option exercises, research deliverables)Return on Collaboration Investment (financial and strategic impact)Pipeline Contribution from External Sources (percentage of portfolio value or assets)10. Resource demand and capacity planning dashboardThe Resource Demand & Capacity Planning Dashboard enables PMOs to forecast, balance, and optimize resource needs across the R&D portfolio over time. It provides forward-looking visibility into demand generated by planned and ongoing studies versus available capacity across key functions such as clinical operations, data management, biostatistics, and regulatory. By identifying future gaps or surpluses early, the dashboard supports proactive hiring, outsourcing, or reprioritization decisions. It also plays a critical role in scenario planning by showing how pipeline changes impact resource requirements and delivery timelines.Key KPIs to Monitor:Forecasted Resource Demand vs. Available CapacityCapacity Gap/SurplusResource Demand by Pipeline Scenario Hiring & Onboarding Lead Time vs. Demand Needs Planned vs. Actual Resource Fulfillment RateFrequently Asked Questions (FAQs) PMO dashboard .faq-wrapper { max-width: 850px; margin: 20px auto; font-family: 'Open Sans', sans-serif; } .faq-item { border-bottom: 1px solid #e0e0e0; padding: 10px 0; } .faq-item summary { font-family: 'Montserrat', sans-serif; font-size: 18px; font-weight: 600; cursor: pointer; list-style: none; position: relative; padding-right: 30px; } /* Remove default marker */ .faq-item summary::-webkit-details-marker { display: none; } /* Down arrow (closed state) */ .faq-item summary::after { content: "▼"; position: absolute; right: 0; top: 0; font-size: 16px; transition: transform 0.3s ease; } /* Up arrow (open state) */ .faq-item[open] summary::after { content: "▲"; } .faq-item p { margin-top: 12px; font-family: 'Open Sans', sans-serif; font-size: 17px; line-height: 1.7; color: #272727; } 1. What is a PMO dashboard in project portfolio management? A PMO dashboard is a centralized, visual decision-support system that consolidates project, financial, risk, and resource data into actionable portfolio insights. 2. Why are PMO dashboards important in pharma R&D? PMO dashboards enable real-time visibility, faster decision-making, and better capital allocation in complex, regulated R&D environments. 3. What are the key types of pharma PMO dashboards? Key dashboards include Portfolio Investment, Clinical Milestone Performance, Resource Capacity, Risk & Issue Management, Cost Tracking, Scenario Planning, and Regulatory Readiness dashboards.

How executive dashboards drive strategic decision making in pharma portfolio management

In the dynamic domain of pharmaceutical research and development, data is emerging as a lifeline where new innovations are transforming our lives every day. The pharmaceutical industry captures an enormous amount of data throughout the drug development process. According to McKinsey, impact of advanced analytics will drive between 15% and 30% improvement of EBIDTA (Earnings Before Interest, Taxes, Depreciation, and Amortization) over the next five years climbing to EBIDTA improvements of between 45% and 70% over the next decade. Given the speed of advancements in the study and knowledge of diseases in today’s world, effective management and analysis of disease data has become the most important performance differentiator for innovative growth in the pharmaceutical industry. The quality and volume of new data collected from academic research, scientific discovery in disease analysis, and advances in pharmaceutical sciences, along with broader and more far-reaching data from epidemiological studies, clinical trial results and real-world evidence is huge. This data cannot be managed or analyzed solely using traditional methods. Pharma R&D organizations must learn to leverage digital aids to assemble this data volume in practical ways that increase their knowledge in diseases of interest and guide their investments in medicine and device therapies. Smart data engineering, business performance monitoring, project management, portfolio risk analysis, intuitive data visualizations, and executive dashboards are becoming an integral part of successful pharma R&D pipeline innovation and delivery. In this blog post, you will discover how decision dashboards play an important role in advancing pharma analytics, R&D project portfolio management and effective decision-making. Top-down, integrated analytic frameworks and dashboards will guide the future of pharmaceutical industry performance. We will explore how visualization and analysis tools should be tailored to meet the unique business growth objectives of strategic business analysts, commercial and R&D portfolio leaders, and corporate executives. For a successful innovative organization, strategic R&D portfolio management is a key factor to growth. Pharma R&D has a very long development cycle and requires the commitment of significant corporate resources to gain approval to market innovative medicine and device therapies. R&D portfolio management solutions help the enterprise control and optimize the value of their investments by analyzing and effectively navigating the risks in their R&D pipelines, and wisely positioning portfolio opportunities to maximize the potential benefit for the company and for their patients. The complexities in pharma portfolio management highlight the need for executive dashboards Diverse Pipeline Components Pharmaceutical companies may manage their R&D project portfolios from early-stage research through loss of exclusivity or by segmenting early-stage and late-stage development and in-line products. Either way you cut it, portfolio management demands alignment in key valuation metrics and the assembly of like for like data on timing, cost, revenue and risk data to effectively inform strategies and decisions. Marketing Dynamics In the highly competitive disease therapy market, portfolio managers analyze various dynamics such as regulatory shifts, research innovations, competitor pipeline advancements, and market trends to differentiate and promote the value of their products for patients. Risk Mitigation and Assessment Risk assessment in drug development accounts for the technical feasibility of demonstrating that a medicine or device delivers health improvements that meet or exceed a minimum criterion for the target product profile, on safety, efficacy, and stability. Beyond that, risk assessments should also account for the uncertainty in regulatory, competitive and commercial forecasts associated with delivering a product with a minimally viable commercial profile. Portfolio Performance Monitoring the performance of projects over time and evaluating them against their baseline, against other projects, or against industry benchmarks for assets at each stage of product development can be effectively achieved through a dynamic visual portfolio dashboard. The comparison analysis enabled by the visual interface can help put focus on performance trends and areas of risk to manage. Effective Decision Making With the ability to incorporate annotations, analytical insights, and rationales into dashboard charts and tables, portfolio investment options can be assessed with expert feedback, and the most viable portfolio development scenarios can be confidently pursued. Importance of Data Visualization in Pharma Portfolio Management The use of dashboards for pharma portfolio analytics drives the value of the organization´s information assets and offers advantage to gaining a competitive edge in a very competitive marketplace. Dashboards collect data from sources across the organization and present them in an interactive and insightful manner, helping executive decision makers access, analyze and act on important information effortlessly. Comprehensive View A holistic, accessible, and appealing visualization of a portfolio incorporates information from distinct data sources such as project delivery milestone timing; project cost and resource forecasts; technical and regulatory risk assessments; competitive landscape analysis; and market forecasts. When presented in an integrated dashboard, these data deliver greater project insights. Real-Time Analytics Integrated decision dashboard, enabled by real-time performance data, help facilitate well-informed decision-making processes. They source plan schedule updates, resource re-allocations, and market forecast adaptations due to competitive, regulatory and market events. These timely information dashboards provide a differentiating advantage for product positioning in a highly competitive industry. Cost Management Pharma Portfolio Executive Dashboard contribute to R&D cost management by efficiently signaling cost variance from baseline, assessing ROI for trial investment and optimizing cost forecasts and benchmarks for future management of trial cost and forecasting. Customization Portfolio management across the pharma industry has a common objective to drive sustained business growth but each organization has its own unique approach to governing its portfolio investment decisions. Subsequently, each organization measures portfolio performance and growth objectives based on the unique metrics and composition of their portfolios. To effectively interact with their portfolio knowledge base, these stakeholders require customized, yet frictionless interaction with their portfolio data, via personalized data dashboards, with data visualizations and insights customized to manage and respond to the elements most sensitive to sustained growth. Challenges in accomplishing Data Visualization for Data- Driven- Decision- Making From long and complex drug development cycles to fast evolving standards of care and an ever-dynamic market landscape, the pharmaceutical industry has a complex task of forecasting a successful and sustainable pipeline delivery of innovative medicine and device therapies over the next decade. Digital solutions such as data visualization and data dashboards improve clarity and actionable insights to effectively project and plan for a sustainable future with a robust and viable set of medicine and device projects at all stages of research and development. Data Disparity and data silos A core challenge that pharma and biotech companies are grappling with is data disparity. Due to the distributed nature of pharma R&D planning and execution, data is captured and maintained in different systems and in varying formats and structures throughout the project lifecycle. Maintaining data standards across systems may not be a priority for the various project data contributors and therefore it may be challenging to assure data quality and to align and join project data for portfolio analysis. This makes it difficult for the portfolio decision makers to get a reliable, consolidated view of all their project data. Manual data assembly demands patience, is error prone, and may not yield insights in a timeframe that a decision maker requires. Need for Centralized Portfolio-level Visualizations A crucial step in data-driven-decision-making is the ability to analyze multiple dimensions of complex project data and to make informed decisions. Dashboards and visualizations can be of immense help in bringing clarity and insight into the performance and options available to optimize a project’s development path. The ability to assess one or many projects in the portfolio, to visualize and contrast projects and development options across the portfolio, and to offer clear insights to investment choices for decision-makers is a significant advantage. As a pioneer in pharma data analytics and visualizations, team i2e engineered Clairvoyance- a custom Executive Dashboard Application tailored specifically for the pharmaceutical industry. This application offers a consolidated view of the client's project portfolio, providing executives with a powerful interactive tool for data-driven decision-making. This custom solution delivers a robust data quality verification platform and offers the analysis and visualization features needed to tackle the various problems the client was experiencing. The Clairvoyance custom dashboard platform can help the R&D leaders to align portfolio performance with their business goals. i2e Consulting helps global pharmaceutical companies to access insights and prepare decision dashboards tailored to their unique business requirements. Embrace the power of Clairvoyance, a cutting-edge decision management solution. Contact us now and seize the future of pharmaceutical innovation by optimizing, strategizing, and thriving with Clairvoyance. Reference: https://www.mckinsey.com/industries/life-sciences/our-insights/how-pharma-can-accelerate-business-impact-from-advanced-analytics

Data Visualization Solutions | Services | Custom Dashboard

Digitalization led to big data which by 2020 will have 44 trillion gigabytes of data. We are in a position where we have access to masses of data, but our ability to effectively use this data for competitive advantage is a constraint. The reason being most of this data is unstructured and scattered across multiple sources. Did you know that only 1% of the data we have access to is analyzed? This is a massive underutilization of data which is not free. Data is helmed as the new age gold and if you are planning to become data rich you should invest in Data Visualization. Data visualization has been around for centuries and evolving constantly. From primitive maps to visualizing data in mixed reality visual representation of data has come a long way. Visualization makes it easier to process and comprehend data. As they say, “A picture tells a story better than 1000 words could” Data visualization can be used at different levels across an organization and there are several used cases. One thing to consider while going for visualization is to have a clear objective whether you want it for exploring the data or mere presentation of data. Data Exploration is used by a data analyst who is trying to match patterns, get insights, make a forecast, etc. These usually require dashboards, multi-layer graphs, etc. Data exploration is used by many businesses to get actionable business insights into their data and plan the next steps. On the other hand, data presentation is to represent the findings of data exploration in a very basic form, usually some form of storytelling. You would not want your investors or higher management to spend time understanding the graphs and charts or worse not understanding them at all. We at i2e consulting offer data visualization to help get actional business insights and PPM solutions. Here we list a few of our many customized data visualization solutions that hugely benefit organizations. Data Exploration in R&D: We created dashboards for a pharmaceutical giant who wanted to get insights on the research and development happening around their organization. They wanted these dashboards to drug lifecycle management. Our dashboards helped R&D productivity to newer heights through complete data integration and cross-departmental data utilization. Interactive mixed-reality PPM dashboards: One of our clients came with a unique requirement wherein they wanted their board meetings to be interesting. They wanted the entire top management to be involved, focused and attentive. We suggested and eventually created data visualization with Microsoft HoloLens. AR/VR is highly engaging, informative and unique (well for now it is) which makes it ideal for presenting information. The holographic imaging enabled them to interact and play around with their data. This newly found perspective not only made the meeting interesting but also enabled better insights for better forecasting. Resourcing Dashboards: Resource planning is one of the key concerns for many organizations because of the nature of the information involved. When one of our clients, requested a dashboard to optimize scheduling and resources precisely. We offered a dashboard solution to minimized resource planning challenges. The dashboard showed resource availability based on skillset, level of expertise that helped with resource availability forecast. Besides, it also showed FTE scores of resources and made the company audit-ready. Wrapping it up, in the age of big data analytics data visualization is the only way to harness information. If you are planning to invest in it, do have a clear objective because these tools do not come cheap. If you are looking for any data visualization solution, we at i2e consulting are ready to answer your queries. Just fill in the below form.